HK1118449A1 - Methods and compositions for treating diabetes, metabolic syndrome and other conditions - Google Patents
Methods and compositions for treating diabetes, metabolic syndrome and other conditionsInfo
- Publication number
- HK1118449A1 HK1118449A1 HK08109611.2A HK08109611A HK1118449A1 HK 1118449 A1 HK1118449 A1 HK 1118449A1 HK 08109611 A HK08109611 A HK 08109611A HK 1118449 A1 HK1118449 A1 HK 1118449A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- conditions
- metabolic syndrome
- compositions
- methods
- treating diabetes
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical class C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000014311 Cushing syndrome Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64305505P | 2005-01-10 | 2005-01-10 | |
| PCT/IB2006/000026 WO2006072881A1 (en) | 2005-01-10 | 2006-01-10 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1118449A1 true HK1118449A1 (en) | 2009-02-13 |
Family
ID=36143322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08109611.2A HK1118449A1 (en) | 2005-01-10 | 2008-08-29 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US20090233843A1 (no) |
| EP (1) | EP1853266B1 (no) |
| JP (1) | JP5358095B2 (no) |
| KR (2) | KR20140030327A (no) |
| CN (1) | CN101141964B (no) |
| AT (1) | ATE528005T1 (no) |
| AU (1) | AU2006204334B2 (no) |
| CA (1) | CA2594433C (no) |
| CY (1) | CY1112519T1 (no) |
| DK (1) | DK1853266T3 (no) |
| ES (1) | ES2377526T3 (no) |
| HK (1) | HK1118449A1 (no) |
| IL (1) | IL184459A (no) |
| MX (1) | MX2007008331A (no) |
| NO (1) | NO339007B1 (no) |
| NZ (1) | NZ560481A (no) |
| PL (1) | PL1853266T3 (no) |
| PT (1) | PT1853266E (no) |
| SI (1) | SI1853266T1 (no) |
| WO (1) | WO2006072881A1 (no) |
| ZA (1) | ZA200706020B (no) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| ES2377526T3 (es) * | 2005-01-10 | 2012-03-28 | Cortendo Ab (Publ) | 2S,4R ketoconazol para el tratamiento de la diabetes, el síndrome metabólico y otras afecciones |
| AU2007204969A1 (en) * | 2006-01-10 | 2007-07-19 | Cortendo Invest Ab | Methods and compositions for treating prostate cancer |
| ZA200902127B (en) * | 2006-10-02 | 2010-07-28 | Cortendo Invest Ab | Ketoconazole enantiomer in humans |
| NZ595852A (en) | 2009-04-29 | 2014-07-25 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
| CN102413825A (zh) | 2009-04-29 | 2012-04-11 | 阿马里纳股份公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| HUE054298T2 (hu) | 2009-06-15 | 2021-08-30 | Amarin Pharmaceuticals Ie Ltd | Készítmények és módszerek stroke kezelésére egy konkomittáns sztatin terápián tartott alanyban |
| EP2480248B1 (en) | 2009-09-23 | 2015-09-02 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| WO2011115955A1 (en) * | 2010-03-15 | 2011-09-22 | Duke University | Identification of a genetic risk factor for diabetes |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| WO2012074930A2 (en) | 2010-11-29 | 2012-06-07 | Amarin Pharma, Inc. | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US10272133B2 (en) | 2011-10-06 | 2019-04-30 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
| US9044433B2 (en) | 2011-10-06 | 2015-06-02 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| AU2013282394B2 (en) | 2012-06-29 | 2018-04-26 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| EP2953625A1 (en) * | 2013-02-06 | 2015-12-16 | Cortendo AB (publ) | Novel functionalized 4-(phenoxymethyl(-1,3-dioxolane analogs exhibiting cytochrome p450 inhibition and their method of use |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| KR20150138225A (ko) * | 2013-03-12 | 2015-12-09 | 에이치엠아이 메디칼 이노베이션즈, 엘엘씨 | 항당뇨병성 및 다른 유용한 활성을 갖는 식물 추출물 |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US11571455B2 (en) | 2013-04-11 | 2023-02-07 | Vanderbilt University | Methods and compositions for treating alcoholic liver disease |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| CN103432135A (zh) * | 2013-09-06 | 2013-12-11 | 天津市康婷生物工程有限公司 | 一种内源性洋地黄样因子抑制剂 |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| US20170151202A1 (en) * | 2015-09-09 | 2017-06-01 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| CN105441391A (zh) * | 2015-12-10 | 2016-03-30 | 湖南中医药大学 | 一种糖尿病并发抑郁症的细胞模型及建立方法和应用 |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| KR102114705B1 (ko) | 2017-11-06 | 2020-05-25 | 연세대학교 산학협력단 | 스타틴에 의한 약물유해반응의 예방 또는 치료용 약학 조성물 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| MA51765A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| WO2020067832A1 (ko) * | 2018-09-28 | 2020-04-02 | 경북대학교 산학협력단 | 티아민 유도체를 포함하는 고코르티솔증 예방 또는 치료용 조성물 |
| WO2020074958A1 (en) * | 2018-10-12 | 2020-04-16 | Strongbridge Dublin Limited | Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism |
| JP2022522873A (ja) * | 2019-03-04 | 2022-04-20 | ストロングブリッジ ダブリン リミテッド | レボケトコナゾールによる疾患の処置方法 |
| WO2020231909A1 (en) * | 2019-05-11 | 2020-11-19 | Steven Hoffman | Compositions and methods for treating bile acid associated diseases |
| US20210251939A1 (en) * | 2020-02-19 | 2021-08-19 | New Frontier Labs, Llc | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions |
| KR102289381B1 (ko) * | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
| EP4326244A1 (en) | 2021-04-21 | 2024-02-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| US20230372312A1 (en) * | 2022-05-20 | 2023-11-23 | Corcept Therapeutics Incorporated | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient |
| WO2024040256A2 (en) * | 2022-08-19 | 2024-02-22 | National Health Research Institutes | Pharmaceutical combinations and methods for preventing or treating neurodegenerative diseases |
| WO2024105519A1 (en) * | 2022-11-14 | 2024-05-23 | Piramal Pharma Limited | A process for the preparation of levoketoconazole |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5432176A (en) * | 1988-11-29 | 1995-07-11 | The John Hopkins University | Method of retarding the progression of chronic renal failure |
| AU5851594A (en) | 1992-12-22 | 1994-07-19 | Georgetown University | Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections |
| WO1994014447A1 (en) | 1992-12-22 | 1994-07-07 | Sepracor, Inc. | Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections |
| US5869255A (en) * | 1994-02-01 | 1999-02-09 | The Regents Of The University Of California | Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis |
| WO1996004912A1 (en) * | 1994-08-09 | 1996-02-22 | Metabolic Syndrome I Gbg Ab | Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes |
| US6642236B1 (en) * | 1998-12-14 | 2003-11-04 | Cortendo Ab | Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis |
| US5584790A (en) * | 1995-09-08 | 1996-12-17 | Beckman Instruments, Inc. | Variable inclination centrifugation assembly for rapid separation of blood |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US5994334A (en) * | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| SE9700642D0 (sv) * | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
| AU749271B2 (en) | 1997-07-01 | 2002-06-20 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| WO2000058360A2 (en) | 1999-03-29 | 2000-10-05 | Uutech Limited | Analogs of gastric inhibitory peptide and their use for treatment of diabetes |
| EP1165519A1 (en) | 1999-04-02 | 2002-01-02 | Neurogen Corporation | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| HUP0201033A3 (en) | 1999-05-17 | 2003-03-28 | Novo Nordisk As | Glucagon antagonists/inverse agonists, process for their preparation and their use |
| GB9915625D0 (en) * | 1999-07-02 | 1999-09-01 | Cortendo Ab | Method |
| PE20010612A1 (es) | 1999-09-28 | 2001-07-12 | Bayer Corp | Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y su uso farmacologico |
| GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
| US20020055512A1 (en) * | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
| GB0118300D0 (en) | 2001-07-26 | 2001-09-19 | Cortendo Ab | Formulations |
| MXPA04007713A (es) * | 2002-02-07 | 2004-11-10 | Pfizer | Uso de inhibidores de la fosfodiesterasa tipo 5, tal como sildenafil, en el tratamiento del sindrome de ovario poliquistico. |
| CA2518409A1 (en) * | 2003-03-12 | 2004-09-23 | John P. Mullally | Composition and method for treating inflammations by reducing c-reactive protein |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| ES2377526T3 (es) * | 2005-01-10 | 2012-03-28 | Cortendo Ab (Publ) | 2S,4R ketoconazol para el tratamiento de la diabetes, el síndrome metabólico y otras afecciones |
| AU2007204969A1 (en) * | 2006-01-10 | 2007-07-19 | Cortendo Invest Ab | Methods and compositions for treating prostate cancer |
| ZA200902127B (en) * | 2006-10-02 | 2010-07-28 | Cortendo Invest Ab | Ketoconazole enantiomer in humans |
-
2006
- 2006-01-10 ES ES06701304T patent/ES2377526T3/es active Active
- 2006-01-10 JP JP2007549979A patent/JP5358095B2/ja active Active
- 2006-01-10 CN CN2006800048108A patent/CN101141964B/zh active Active
- 2006-01-10 US US11/813,662 patent/US20090233843A1/en not_active Abandoned
- 2006-01-10 NZ NZ560481A patent/NZ560481A/en not_active IP Right Cessation
- 2006-01-10 AU AU2006204334A patent/AU2006204334B2/en active Active
- 2006-01-10 KR KR1020147002595A patent/KR20140030327A/ko not_active Application Discontinuation
- 2006-01-10 PL PL06701304T patent/PL1853266T3/pl unknown
- 2006-01-10 KR KR1020077017684A patent/KR101387910B1/ko active IP Right Grant
- 2006-01-10 ZA ZA200706020A patent/ZA200706020B/xx unknown
- 2006-01-10 EP EP06701304A patent/EP1853266B1/en active Active
- 2006-01-10 SI SI200631232T patent/SI1853266T1/sl unknown
- 2006-01-10 CA CA2594433A patent/CA2594433C/en active Active
- 2006-01-10 MX MX2007008331A patent/MX2007008331A/es active IP Right Grant
- 2006-01-10 WO PCT/IB2006/000026 patent/WO2006072881A1/en active Application Filing
- 2006-01-10 PT PT06701304T patent/PT1853266E/pt unknown
- 2006-01-10 DK DK06701304.5T patent/DK1853266T3/da active
- 2006-01-10 AT AT06701304T patent/ATE528005T1/de active
-
2007
- 2007-07-05 IL IL184459A patent/IL184459A/en active IP Right Grant
- 2007-08-09 NO NO20074117A patent/NO339007B1/no not_active IP Right Cessation
-
2008
- 2008-08-29 HK HK08109611.2A patent/HK1118449A1/xx active IP Right Revival
-
2012
- 2012-01-12 CY CY20121100037T patent/CY1112519T1/el unknown
-
2016
- 2016-04-01 US US15/088,539 patent/US9918984B2/en active Active
-
2018
- 2018-02-01 US US15/886,437 patent/US10098877B2/en active Active
- 2018-10-04 US US16/152,202 patent/US10517868B2/en active Active
-
2019
- 2019-12-16 US US16/715,690 patent/US10835530B2/en active Active
-
2020
- 2020-11-10 US US17/094,544 patent/US11478471B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1118449A1 (en) | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | |
| DE602007004324D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| TW200745052A (en) | Thyroid hormone receptor agonists | |
| MY148128A (en) | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| DE602007007473D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| PL2029529T3 (pl) | PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1 | |
| WO2007124337A8 (en) | Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1 | |
| WO2007127763A3 (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| DE602004011985D1 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
| TW200637874A (en) | Peptides with neuropeptide-2 receptor (Y2R) agonist activity | |
| TW200806311A (en) | Neuropeptide-2 receptor-agonists | |
| WO2010036613A8 (en) | Novel cyclic benzimidazole derivatives useful anti-diabetic agents | |
| IL194879A0 (en) | Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| ES2318577T3 (es) | Derivados de cicloalquil lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1'. | |
| IL176648A0 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| PL2049475T3 (pl) | Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1 | |
| IN2012DN03023A (no) | ||
| MX2007007183A (es) | Aminas, combinacion de aminas y vanadio y sales de amina y vanadio para el tratamiento o prevencion de dislipidemia. | |
| HK1097406A1 (en) | Selective peroxisome proliferator activated receptor modulators | |
| UA90039C2 (en) | Neuropeptide-2 receptor-agonists | |
| UA83265C2 (ru) | Селективные модуляторы рецепторов, которые активируются пролифераторами пероксисом | |
| UA90264C2 (ru) | Три(цикло)замещенные амиды, фармацевтическая композиция, способы лечения и профилактики, способ получения соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230107 |
|
| ARF | Application filed for restoration |
Effective date: 20240104 |
|
| ARG | Restoration of standard patent granted |
Effective date: 20240426 |